Original news and analysis on international IP policy
Non-profit patent researchers studying the most prominent prescription insulin drug to treat diabetes in the United States found it is “overpatented” and “overpriced,” enabling unwarranted price-hikes resulting in rising costs for patients and taxpayers.
Universities Allied for Essential Medicines (UAEM) announced today that University of Calgary and McGill University are joining University of British Columbia in adopting Global Access Licensing Principles. These principles promote public access to publicly-funded medicines and life-saving health technologies developed in universities, according to a UAEM press release [pdf].
French advocacy group La Quadrature du Net has declared recent French government plans to regulate internet hate speech insufficient, and is calling for more in-depth reforms. These could include the promotion of alternative social media platforms and a decentralised approach to regulation, according to an organisation press release.
Public Knowledge, a Washington, DC advocacy group, today released a paper calling for the formation of a new federal government authority to develop expertise and capacity on artificial intelligence (AI), to be able to effectively regulate and govern these technologies in the future.
A new US private sector report asserts that China is gaining the inside track on international standard-setting for “Internet of Things” technology, and offers strategies for the United States to keep competitive in the marketplace by maintaining influence over standard-setting while protecting data security.
A new report reviews how patent linkage mechanisms have been implemented in South Korea, Australia, Canada, and the United States, and identifies precedents for how low and middle-income countries (LMICs) can retain and exploit “constructive ambiguities” in trade treaty text to mitigate the impacts of patent linkage mechanisms and promote the timely availability of generic medicines.
The United States Department of Health and Human Services has released a new plan intended to reduce drug prices for some patients on Medicare, based on an international pricing index model. In his announcement of the plan, President Trump said the US would save money “for our seniors by paying the prices other countries pay. Nothing special, just the prices that other countries pay.”
Monopoly prices of diagnostic tools and lack of competition in the market constitute a barrier to treatment for people with hepatitis C virus (HCV), but the increased use of “open” diagnostic platforms could reduce prices, a health advocacy research study has found.
Generics industry group Medicines for Europe has declared United States interference in the European Union legislative process on the supplementary protection certificate (SPC) manufacturing waiver “unacceptable,” and an attempt to “influence the outcome of this EU legislative proposal.”
The Group of 77 developing countries plus China delivered a statement at the recent United Nations High-Level Meeting on Tuberculosis, calling for forward progress on the commitments to funding and action made in the UN political declaration on TB.
The tricontinental research group “accessibsa” has found that while the Indian Patent Office rejects 40 percent of pharmaceutical patent applications, it should be rejecting 90 percent of applications to comply with Indian patent law, according to the results of its recent study of Indian patent data.
A new report, “The People's Prescription: Re-imagining health innovation to deliver public value,” calls for restructuring research and development innovation systems to create, rather than extract, value. It also calls for long-term “mission-oriented” public investment, and a public return on this investment.